---
- :id: aHR0cDovL3d3dy5zYW5vZmkuY29tL0M2Njc4NC9WMSNDNjY3ODQ=
  :uri: http://www.sanofi.com/C66784/V1#C66784
  :rdf_type: http://www.assero.co.uk/Thesaurus#ManagedConcept
  :label: Common Terminology Criteria for Adverse Events V3.0
  :tagged:
  - http://www.assero.co.uk/CSN#2070e714-3f5b-45d4-b1a3-5ff5d58cbce9
  :has_state: http://www.sanofi.com/C66784/V1#C66784_RS
  :has_identifier: http://www.sanofi.com/C66784/V1#C66784_SI
  :origin: ''
  :change_description: ''
  :creation_date: '2013-04-12T00:00:00+00:00'
  :last_change_date: '2020-05-26T14:37:15+02:00'
  :explanatory_comment: ''
  :identifier: C66784
  :notation: TOXGRV3
  :definition: A standard terminology developed to report adverse events occurring
    in cancer clinical trials. Common terminology criteria for adverse events (CTCAE)
    are used in study adverse event summaries and Investigational New Drug reports
    to the Food and Drug Administration. The CTCAE contain a grading scale for each
    adverse event term representing the severity of the event. (NCI)
  :extensible: false
  :narrower:
  - http://www.cdisc.org/C66784/V4#C66784_C41338
  - http://www.cdisc.org/C66784/V4#C66784_C41339
  - http://www.cdisc.org/C66784/V17#C66784_C41340
  - http://www.cdisc.org/C66784/V28#C66784_C48275
  - http://www.cdisc.org/C66784/V28#C66784_C41337
  :extends: 
  :subsets: 
  :preferred_term: http://www.assero.co.uk/PT#ba13dba4cca13c241718cb294412a7e0dd2479c4
  :synonym:
  - http://www.assero.co.uk/SYN#33add2386b696b597921a949e63aba2e2bfd945f
  :is_ordered: 
  :is_ranked: 
- :id: aHR0cDovL3d3dy5zYW5vZmkuY29tL0M4NzE2Mi9WMSNDODcxNjI=
  :uri: http://www.sanofi.com/C87162/V1#C87162
  :rdf_type: http://www.assero.co.uk/Thesaurus#ManagedConcept
  :label: Common Terminology Criteria for Adverse Events V4.0
  :tagged:
  - http://www.assero.co.uk/CSN#2070e714-3f5b-45d4-b1a3-5ff5d58cbce9
  :has_state: http://www.sanofi.com/C87162/V1#C87162_RS
  :has_identifier: http://www.sanofi.com/C87162/V1#C87162_SI
  :origin: ''
  :change_description: ''
  :creation_date: '2012-12-21T00:00:00+00:00'
  :last_change_date: '2020-05-26T14:37:15+02:00'
  :explanatory_comment: ''
  :identifier: C87162
  :notation: TOXGRV4
  :definition: The version 4.0 standard terminology developed to report adverse events
    occurring in cancer clinical trials. Common terminology criteria for adverse events
    (CTCAE) are used to study adverse event summaries and Investigational New Drug
    reports to the Food and Drug Administration. The CTCAE contain a grading scale
    for each adverse event term representing the severity of the event. (NCI)
  :extensible: false
  :narrower:
  - http://www.cdisc.org/C87162/V19#C87162_C84265
  - http://www.cdisc.org/C87162/V19#C87162_C84263
  - http://www.cdisc.org/C87162/V19#C87162_C84266
  - http://www.cdisc.org/C87162/V19#C87162_C48275
  - http://www.cdisc.org/C87162/V19#C87162_C84264
  - http://www.cdisc.org/C87162/V27#C87162_C75533
  :extends: 
  :subsets: 
  :preferred_term: http://www.assero.co.uk/PT#c4d6ca8f9e6316b52b9ce962fbe35c0c5d7e9206
  :synonym:
  - http://www.assero.co.uk/SYN#fafe8d77e59bfa229f9f775fe3d0d3b340fb30dd
  :is_ordered: 
  :is_ranked: 
- :id: aHR0cDovL3d3dy5zYW5vZmkuY29tL0M2Njc2OC9WMSNDNjY3Njg=
  :uri: http://www.sanofi.com/C66768/V1#C66768
  :rdf_type: http://www.assero.co.uk/Thesaurus#ManagedConcept
  :label: Outcome of Event
  :tagged:
  - http://www.assero.co.uk/CSN#2070e714-3f5b-45d4-b1a3-5ff5d58cbce9
  :has_state: http://www.sanofi.com/C66768/V1#C66768_RS
  :has_identifier: http://www.sanofi.com/C66768/V1#C66768_SI
  :origin: ''
  :change_description: ''
  :creation_date: '2011-12-09T00:00:00+00:00'
  :last_change_date: '2020-05-26T14:37:15+02:00'
  :explanatory_comment: ''
  :identifier: C66768
  :notation: OUT
  :definition: A condition or event that is attributed to the adverse event and is
    the result or conclusion of the adverse event. (NCI)
  :extensible: false
  :narrower:
  - http://www.cdisc.org/C66768/V4#C66768_C49496
  - http://www.cdisc.org/C66768/V4#C66768_C17998
  - http://www.cdisc.org/C66768/V4#C66768_C49498
  - http://www.cdisc.org/C66768/V4#C66768_C49495
  - http://www.cdisc.org/C66768/V4#C66768_C49494
  - http://www.cdisc.org/C66768/V28#C66768_C48275
  :extends: 
  :subsets: 
  :preferred_term: http://www.assero.co.uk/PT#d60d08c1aaca92fc9aa7ccc4b9b2185cfc831895
  :synonym:
  - http://www.assero.co.uk/SYN#5b469418e7549e77ea6e369f4d7406933c771b1e
  :is_ordered: 
  :is_ranked: 
- :id: aHR0cDovL3d3dy5zYW5vZmkuY29tL0M2Njc2OS9WMSNDNjY3Njk=
  :uri: http://www.sanofi.com/C66769/V1#C66769
  :rdf_type: http://www.assero.co.uk/Thesaurus#ManagedConcept
  :label: Severity/Intensity Scale for Adverse Events
  :tagged:
  - http://www.assero.co.uk/CSN#2070e714-3f5b-45d4-b1a3-5ff5d58cbce9
  :has_state: http://www.sanofi.com/C66769/V1#C66769_RS
  :has_identifier: http://www.sanofi.com/C66769/V1#C66769_SI
  :origin: ''
  :change_description: ''
  :creation_date: '2009-07-06T00:00:00+00:00'
  :last_change_date: '2020-05-26T14:37:15+02:00'
  :explanatory_comment: ''
  :identifier: C66769
  :notation: AESEV
  :definition: A scale that defines the degree or state of disease existing in a patient
    as a result of the occurrence of an adverse event. (NCI)
  :extensible: false
  :narrower:
  - http://www.cdisc.org/C66769/V4#C66769_C41338
  - http://www.cdisc.org/C66769/V4#C66769_C41339
  - http://www.cdisc.org/C66769/V17#C66769_C41340
  :extends: 
  :subsets: 
  :preferred_term: http://www.assero.co.uk/PT#76edd4e6a61216f70444c66f1177f9755ecc7de9
  :synonym:
  - http://www.assero.co.uk/SYN#de32aa5ed1ed0f70b85bd61ff51cda8cd2af17a2
  :is_ordered: 
  :is_ranked: 
